Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 3/20 | 0.42 |
| ▸ | ARG2 | P78540 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31080989 | 1.00 | ARG1 (0.42) | ARG1ARG2TAAR1SLC1A2SMN1; SMN2 | |
| SCHEMBL1818499 | 0.85 | ARG1 (0.45) | ARG1ARG2SLC1A2 | |
| SCHEMBL7362997 | 0.85 | ARG1 (0.45) | ARG1ARG2SLC1A2 | |
| SCHEMBL31080858 | 0.84 | ARG1 (0.42) | ARG1ARG2SLC1A2 | |
| SCHEMBL1816822 | 0.84 | ARG1 (0.42) | ARG1ARG2SLC1A2 | |
| SCHEMBL31080883 | 0.84 | ARG1 (0.42) | ARG1ARG2SLC1A2 | |
| SCHEMBL31080905 | 0.84 | ARG1 (0.42) | ARG1ARG2SLC1A2 | |
| SCHEMBL1820924 | 0.84 | ARG1 (0.42) | ARG1ARG2SLC1A2 | |
| SCHEMBL1814718 | 0.84 | MEN1 (0.43) | ARG1ARG2SLC1A2 | |
| SCHEMBL2507417 | 0.84 | ARG1 (0.42) | ARG1ARG2SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240247034-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | GENENTECH INC (US) | 2024-07-25 | — | — | US | claimed |
| US-20230174596-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | GENENTECH INC (US) | 2023-06-08 | — | — | US | claimed |
| CN-114805528-A | Cystine knot scaffold platform | 豪夫迈·罗氏有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-114591422-A | Cystine knot scaffold platform | 豪夫迈·罗氏有限公司 | 2022-06-07 | — | — | CN | claimed |
| US-20200325187-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | GENENTECH, INC. (US) | 2020-10-15 | — | — | US | claimed |
| US-20200231636-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | GENENTECH INC (US) | 2020-07-23 | — | — | US | claimed |
| US-20180291069-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | GENENTECH INC (US) | 2018-10-11 | — | — | US | claimed |
| EP-3350215-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | H. Hoffnabb-La Roche Ag (CH) | 2018-07-25 | — | — | EP | claimed |
| US-20170129927-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | GENENTECH INC (US) | 2017-05-11 | — | — | US | claimed |
| WO-2017049009-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | GENENTECH, INC. (US) | 2017-03-23 | — | — | WO | claimed |
| EP-3350215-B1 | CYSTINE KNOT SCAFFOLD PLATFORM | HOFFMANN LA ROCHE (CH) | 2025-12-03 | — | — | EP | disclosed |
| US-20240247034-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | GENENTECH INC (US) | 2024-07-25 | — | — | US | disclosed |
| CN-113967258-B | FAP-activated therapeutic agents and related uses | 塔夫茨大学信托人 | 2024-07-02 | — | — | CN | disclosed |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| WO-2024130161-A2 | NOVEL CAMPTOTHECIN DERIVATIVES AND CONJUGATES THEREOF | BIONECURE THERAPEUTICS INC (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2008116053-A2 | FAP-ACTIVATED CHEMOTHERAPEUTIC COMPOUNDS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-1948243-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | Aeris Therapeutics, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008022015-A2 | RETRO-INVERSO INCRETIN ANALOGUES, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007055950-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | AERIS THERAPEUTICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070110813-A1 | Polycation-polyanion complexes, compositions and methods of use thereof | AERIS THERAPEUTICS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | ARG1 1689/4885ARG2 2296/4885TAAR1 4375/4885 |
| US-20240247034-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | LRP6, LDLR, KDR | ARG1 2617/4885ARG2 2888/4885TAAR1 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.